PULM Overview

Pulmatrix, Inc. is a biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to enhance therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. iSPERSE is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for efficient drug delivery and deep penetration into the lungs.

Wall Street analysts forecast PULM stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PULM is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Pulmatrix Inc revenue for the last quarter amounts to 0.00 USD, decreased

Pulmatrix Inc. EPS for the last quarter amounts to -0.32 USD, decreased -36.00

Pulmatrix Inc (PULM) has 2 emplpoyees as of May 31 2026.

Today PULM has the market capitalization of 5.08M USD.